ReviewCirculation2024
Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation.
Review in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Chemotherapy cardiotoxicity research in cancer patients: a bibliometric and visual analysis (1994-2024).Frontiers in oncology · 2025Pooled it
- Systemic administration of the PRMT5 inhibitor GSK3326595 does not induce overt cardiotoxicity in the murine heart.Journal of molecular and cellular cardiology plus · 2026Article
- Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.European heart journal · 2026Article
- PD-1/PD-L1 in Myocarditis: Transcriptional Signals, Functional Questions.JACC. Basic to translational science · 2026Article
- Greenness exposure across the cancer continuum: The role of coronary heart disease.Environmental epidemiology (Philadelphia, Pa.) · 2026Article
- Cardiovascular risks in men with prostate cancer: a pragmatic, clinician-oriented review of risk stratification and management strategies.Prostate cancer and prostatic diseases · 2026Review
- RNAi-mediated p38δ silencing mitigates anthracycline cardiotoxicity in female mice.American journal of physiology. Heart and circulatory physiology · 2026Article
- PD-L1 in ICI Myocarditis: When the Immune Brake Fails.JACC. CardioOncology · 2026Article
- Risk of incident cardiovascular disease events among older Asian, Native Hawaiian, and Pacific Islander colorectal cancer survivors in the United States: a cohort study.Cardio-oncology (London, England) · 2026Article
- Soluble neprilysin and the translational continuum in cardio-oncology.Cardio-oncology (London, England) · 2026Article
- A transformer-based survival model for prediction of all-cause mortality in patients with heart failure: a multi-cohort study.NPJ digital medicine · 2026Article
- Cardio-oncology in multidisciplinary synergy: addressing the rising burden of cancer therapy-related cardiovascular toxicity (CTR-CVT) in advancing oncology practices.Oncology reviews · 2026Review
- Nebivolol Inhibits Hepatocellular Carcinoma via RHOQ and Enhances the Efficacy of Lenvatinib.International journal of biological sciences · 2026Article
- Frailty Meets Cardio-oncology: A New Frontier in Personalised Cancer Care.European cardiology · 2026Review
- Disparities and trends in drug-related adverse reaction mortality in the United States, 1999-2020.Therapeutic advances in drug safety · 2026Article
- Integrated Cardio-oncology Service.Cardiac failure review · 2026Review
- Advancing precision cardio-oncology: multimodal surveillance and stratified management of immunotherapy-induced cardiovascular toxicity.Frontiers in cardiovascular medicine · 2026Review
- Anthracycline-induced left atrioventricular dyssynchrony in children with leukemia: a cardiac magnetic resonance imaging study of functional and strain analysis.Frontiers in cardiovascular medicine · 2026Article
- Social Determinants of Health in Cardio Oncology, from Evidence To Action: Translating Concepts into Clinical Practice Through Implementation Science.Current treatment options in oncology · 2025Review
- Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.